Top Page
China Traditional Chinese Medicine Holdings Co
(OTC:0570)
China Traditional Chinese Medicine Holdings Co (0570) vs. iShares MSCI Hong Kong ETF (EWH)
China Traditional Chinese Medicine Holdings Co Business Overview & Revenue Model
China Traditional Chinese Medicine Holdings Co Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 16.51B | 18.12B | 14.30B | 19.05B | 14.81B |
| Gross Profit | 7.86B | 9.27B | 7.20B | 11.83B | 9.13B |
| EBITDA | 1.82B | 2.56B | 2.16B | 3.59B | 3.16B |
| Net Income | 54.07M | 1.29B | 764.49M | 1.93B | 1.66B |
Balance Sheet | |||||
| Total Assets | 35.06B | 37.07B | 35.62B | 36.39B | 33.09B |
| Cash, Cash Equivalents and Short-Term Investments | 5.34B | 3.69B | 3.67B | 4.14B | 5.03B |
| Total Debt | 4.02B | 5.16B | 5.04B | 5.06B | 5.22B |
| Total Liabilities | 11.13B | 13.13B | 12.67B | 13.73B | 12.19B |
| Stockholders Equity | 21.20B | 21.16B | 20.17B | 19.72B | 18.06B |
Cash Flow | |||||
| Free Cash Flow | 2.07B | 680.20M | 565.09M | -81.17M | -1.02B |
| Operating Cash Flow | 2.58B | 1.17B | 1.09B | 796.03M | 228.47M |
| Investing Cash Flow | -379.24M | -477.62M | -374.15M | -536.94M | -1.07B |
| Financing Cash Flow | -1.39B | -584.31M | -557.28M | -724.32M | -1.01B |
China Traditional Chinese Medicine Holdings Co Technical Analysis
China Traditional Chinese Medicine Holdings Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $10.88B | 197.41 | -1.26% | 3.62% | -9.58% | -128.83% | |
51 Neutral | $7.95B | -0.40 | -42.50% | 2.21% | 22.29% | -1.85% | |
| ― | $1.97B | ― | -1.87% | 5.40% | ― | ― | |
| ― | €1.47B | 9.90 | 25.92% | ― | ― | ― | |
74 Outperform | HK$6.56B | 7.35 | 10.85% | 5.82% | -20.64% | -25.39% | |
70 Outperform | HK$10.37B | 11.11 | 8.62% | 4.02% | 2.32% | -14.41% | |
65 Neutral | ― | ― | -42.02% | -76.29% |
China Traditional Chinese Medicine Holdings Co Corporate Events
China Traditional Chinese Medicine Holdings Co. Limited has appointed Mr. Peng Li as an executive director and a member of the strategic committee, effective July 25, 2025. Mr. Peng brings extensive experience in traditional Chinese medicine and leadership roles within the healthcare sector, which is expected to bolster the company’s strategic direction and operational expertise.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the composition of its board of directors, detailing the roles and functions of each member. This organizational update provides insights into the company’s governance structure, which may influence its strategic decisions and operational effectiveness, potentially impacting stakeholders’ interests and the company’s positioning in the traditional medicine industry.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has issued a profit warning, indicating an expected decline in net profit by 165% to 175% for the first half of 2025 compared to the previous year. The decline is attributed to reduced revenue and profitability in its concentrated TCM granules business due to increased centralized procurement and market competition, as well as a provision for goodwill impairment. This impairment is non-cash and aims to position the company for future improvements, with the expectation that profit would decrease by 50% to 60% without the impairment effect.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced that the resolution to appoint BDO as the auditor of the company was passed at the Extraordinary General Meeting held on 18 July 2025. The resolution received unanimous support from shareholders, indicating strong backing for the company’s governance decisions and potentially reinforcing investor confidence.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$4.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced an extraordinary general meeting scheduled for July 18, 2025, to appoint BDO as the company’s auditor and authorize the board to fix the auditor’s remuneration. This meeting is significant for stakeholders as it involves key decisions regarding the company’s financial oversight, potentially impacting its governance and operational transparency.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced that all resolutions proposed at its Annual General Meeting on June 27, 2025, were approved by shareholders. This includes the approval of financial statements, the declaration of dividends, and the re-election of directors, reflecting strong shareholder support and stable governance, which may positively impact the company’s market position and stakeholder confidence.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced that the National Medical Products Administration of China has accepted the new drug application for Yushuda Tablets, an innovative traditional Chinese medicine developed by its subsidiary, Sinopharm Group Tongjitang Pharmaceutical. Yushuda Tablets have shown significant efficacy in treating mild-to-moderate depression, particularly symptoms related to qi stagnation. The acceptance marks a critical step in the regulatory process, although the timeline for approval remains uncertain, and the company advises caution to shareholders and investors.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced adjustments to its board committees, effective June 20, 2025. These changes involve the re-designation of non-executive directors Ms. Xu Jinghui, Mr. Zu Jing, and Mr. Liu Haijian to different board committees, aiming to enhance the company’s governance structure and compliance with Hong Kong Stock Exchange listing rules. The adjustments are intended to strengthen board effectiveness and diversity, thereby improving corporate governance practices.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the composition of its board of directors, which includes executive, non-executive, and independent non-executive directors. The announcement also details the membership of various board committees, indicating a structured governance approach that may enhance decision-making and strategic planning within the company.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the formation of a Nomination Committee to enhance its corporate governance. The committee, comprising both executive and non-executive directors, is tasked with reviewing the board’s structure and composition to align with the company’s strategic goals. This move is expected to strengthen the company’s governance framework and ensure a diverse and skilled board, potentially impacting its strategic direction and stakeholder confidence.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the proposed appointment of BDO Limited as its new auditor, replacing Ernst & Young, which will retire at the conclusion of the upcoming AGM. The decision, recommended by the company’s audit committee, considers BDO’s market reputation, technical competence, and independence, and is deemed beneficial for the company’s stakeholders.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited issued a clarification announcement regarding an inadvertent clerical error in its annual general meeting circular and notice. The error pertained to the closure period of the register of members for dividend entitlement. The corrected period is from 7 July 2025 to 9 July 2025, during which no share transfers will be registered. This announcement ensures shareholders are accurately informed about the dividend payment process, maintaining transparency and trust.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 27, 2025, where shareholders will consider the company’s audited financial statements and reports for the year ending December 31, 2024. The board has proposed a final dividend of HK0.35 cent per share and a special dividend of HK8.30 cents per share. Additionally, the meeting will involve the re-election of several directors and the authorization of the board to set directors’ remuneration. This announcement reflects the company’s commitment to rewarding shareholders and maintaining strong governance practices.
The most recent analyst rating on (HK:0570) stock is a Hold with a HK$2.60 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced the retirement of Ernst & Young as its auditor due to regulatory requirements limiting the tenure of auditing firms for state-owned enterprises. The company assured stakeholders that this change will not impact its financial reporting for the year ending December 2025 and is actively seeking a new auditor.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced the postponement of its Annual General Meeting (AGM) from June 18, 2025, to June 27, 2025, to allow more preparation time. Consequently, the book closure periods and record dates for shareholders’ entitlements to attend the AGM and receive dividends have been adjusted. The payment date for the final and special dividends for the year ended December 31, 2024, has also been rescheduled to July 18, 2025, pending shareholder approval. These changes may impact stakeholders’ planning and financial expectations.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced a final cash dividend of HKD 0.0035 per share for the financial year ending December 31, 2024. The dividend is set to be approved by shareholders on June 27, 2025, with payment scheduled for July 18, 2025. This announcement reflects the company’s ongoing financial health and commitment to providing returns to its shareholders, which may positively influence investor confidence and market perception.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited has announced a special cash dividend of HKD 0.083 per share for the financial year ending December 31, 2024. This announcement, updated on May 27, 2025, includes details on the dividend’s approval date, ex-dividend date, and payment date, reflecting the company’s commitment to returning value to its shareholders.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.
China Traditional Chinese Medicine Holdings Co. Limited announced key leadership changes, including the retirement of Mr. LAN Qingshan and the resignation of Mr. ZHAO Dongji and Mr. HUANG Zhangxin from their vice president roles due to work arrangement changes. Mr. ZHAO also stepped down as joint company secretary, with Ms. NG Sau Mei assuming the sole company secretary role. Mr. ZHENG Jun has been appointed as a new vice president, bringing extensive experience from Sino Pharmengin Corporation. Additionally, Mr. LI Hongjian has been appointed as the new authorised representative, reflecting the company’s strategic leadership restructuring.
The most recent analyst rating on (HK:0570) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on China Traditional Chinese Medicine Holdings Co stock, see the HK:0570 Stock Forecast page.